Hengruis Patent: A Catalyst in the GLP-1 Arena Hengruis patent, part of its $6B licensing deal with Hercules CM NewCo (Pharmaceutical Technology, 2024), covers innovative GLP-1/GIP dual agonists like HRS-9531 and oral small molecules like HRS-7535, both in Phase II/III trials for obesity and type 2 diabetes (Synapse PatSnap, 2024)
American Academy of Clinical Toxicology
Glutathione S-transferases Control astrocyte activation and neuronal health during [PMID: 36685285] Laboratory literature summary: Glutathione S-transferases Control astrocyte activation and neuronal health during neuroinflammation
Products detained at customs are often destroyedimporting these formulations carries legal and safety risk
Unlike GLP-1, GIP doesnt significantly slow gastric emptying
ISPOR 2026: AI-enabled insights to drive evidence strategy Join us at ISPOR on May 18 at 3:15pm, where Truvetas SVP of Product Michael Simonov , MD will share how AI can compress that timeline, enabling health economics and outcomes research (HEOR) teams to generate answers in minutes, not months